About Vaxcyte
Vaxcyte is a company based in Foster City (United States) founded in 2013 by Jeff Fairman.. Vaxcyte has raised $347 million across 8 funding rounds from investors including TPG, HHS and Janus Henderson Investors. The company has 414 employees as of December 31, 2024. Vaxcyte offers products and services including VAX-31 and VAX-24. Vaxcyte operates in a competitive market with competitors including Biological E, Vir Biotechnology, Cidara Therapeutics, Freeline and Valneva, among others.
- Headquarter Foster City, United States
- Employees 414 as on 31 Dec, 2024
- Founders Jeff Fairman
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Vaxcyte, Inc.
-
Annual Revenue
$00as on Dec 31, 2024
-
Net Profit
$-463.93 M-15.33as on Dec 31, 2024
-
EBITDA
$-553.7 M-44.62as on Dec 31, 2024
-
Total Equity Funding
$347 M (USD)
in 8 rounds
-
Latest Funding Round
$110 M (USD), Series D
Apr 03, 2020
-
Investors
TPG
& 12 more
-
Employee Count
414
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Vaxcyte
Vaxcyte is a publicly listed company on the NASDAQ with ticker symbol PCVX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Vaxcyte
Vaxcyte offers a comprehensive portfolio of products and services, including VAX-31 and VAX-24. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Vaccine designed to prevent invasive pneumococcal disease in children and adults.
Vaccine for protection against pneumococcal infections through advanced immunogenicity.
Unlock access to complete
Unlock access to complete
Leadership Team
45 people
Software Development Team
38 people
Product Management Team
24 people
Senior Team
23 people
Human Resources and Administration
8 people
Operations Team
7 people
Scientific Team
7 people
Finance and Accounting
6 people
Unlock access to complete
Funding Insights of Vaxcyte
Vaxcyte has successfully raised a total of $347M across 8 strategic funding rounds. The most recent funding activity was a Series D round of $110 million completed in April 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 8
- Last Round Series D — $110.0M
-
First Round
First Round
(01 Dec 2013)
- Investors Count 13
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr, 2020 | Amount | Series D - Vaxcyte | Valuation | RA Capital Management , Janus Henderson Investors | |
| Sep, 2019 | Amount | Grant - Vaxcyte | Valuation |
investors |
|
| Jun, 2018 | Amount | Series C - Vaxcyte | Valuation | TPG |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Vaxcyte
Vaxcyte has secured backing from 13 investors, including institutional and venture fund investors. Prominent investors backing the company include TPG, HHS and Janus Henderson Investors. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Multiple sectors are targeted for venture capital investments.
|
Founded Year | Domain | Location | |
|
Fund of funds focused on pre-seed and seed-stage companies
|
Founded Year | Domain | Location | |
|
Private equity firm focused on life science sector
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Vaxcyte
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Vaxcyte
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Vaxcyte Comparisons
Competitors of Vaxcyte
Vaxcyte operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biological E, Vir Biotechnology, Cidara Therapeutics, Freeline and Valneva, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Vaccines and therapeutics for multiple diseases are developed and marketed.
|
|
| domain | founded_year | HQ Location |
Developer of therapeutics for the treatment of infectious diseases
|
|
| domain | founded_year | HQ Location |
Novel anti-infectives for bacterial and fungal infections are developed.
|
|
| domain | founded_year | HQ Location |
Gene therapy platform is developed for chronic disease treatments.
|
|
| domain | founded_year | HQ Location |
Prophylactic vaccines for infectious diseases are developed and advanced.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Vaxcyte
Frequently Asked Questions about Vaxcyte
When was Vaxcyte founded?
Vaxcyte was founded in 2013.
Where is Vaxcyte located?
Vaxcyte is headquartered in Foster City, United States. It is registered at Foster City, California, United States.
Is Vaxcyte a funded company?
Vaxcyte is a funded company, having raised a total of $347M across 8 funding rounds to date. The company's 1st funding round was a Series C of $85M, raised on Dec 01, 2013.
How many employees does Vaxcyte have?
As of Dec 31, 2024, the latest employee count at Vaxcyte is 414.
What does Vaxcyte do?
Vaxcyte was founded in 2013 in Foster City, United States, within the biotechnology sector. Focus is placed on developing vaccines against infectious diseases through the XpressCF platform and proprietary knowledge for protein carriers and antigens. Site-specific conjugation is employed to create building blocks for pneumococcal conjugate vaccines like VAS-24. Efforts target invasive pneumococcal diseases, otitis media, strep infections, and periodontitis.
Who are the top competitors of Vaxcyte?
Vaxcyte's top competitors include Serum Institute of India, Biological E and RedHill Biopharma.
What products or services does Vaxcyte offer?
Vaxcyte offers VAX-31 and VAX-24.
Is Vaxcyte publicly traded?
Yes, Vaxcyte is publicly traded on NASDAQ under the ticker symbol PCVX.
Who are Vaxcyte's investors?
Vaxcyte has 13 investors. Key investors include TPG, HHS, Janus Henderson Investors, RA Capital, and CARB-X.
What is Vaxcyte's ticker symbol?
The ticker symbol of Vaxcyte is PCVX on NASDAQ.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.